Compare iShares MSCI ACWI ETF (ACWI) vs Baxter International Inc (BAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Baxter International Inc — how do they compare? iShares MSCI ACWI ETF trades at $161.53, while Baxter International Inc trades at $27.09 (market cap $14.27B). The key difference: Baxter International Inc pays a 0.14% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Baxter International Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | BAX | |
|---|---|---|
52-Week High | $161.44 | $28.35 |
52-Week Low | $132.04 | $15.80 |
Market Cap | — | $14.27B |
Sector | — | Health |
Enterprise Value | — | $21.79B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $161.72, up 0.38% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The ETF's forward P/E of 15.5x, as of Seeking Alpha on 2026-07-07, suggests reasonable valuation amid robust earnings growth, with Information Technology now comprising 32% of holdings. A dividend of $1.01 is scheduled for June 2026.
Outlook remains positive due to strong EPS growth and institutional interest, though overbought RSI levels near 74.95 signal caution. Risks include market volatility from AI-driven inflows and potential sector concentration, but analyst sentiment supports a buy rating for long-term global equity exposure.
Baxter International (BAX) trades at $27.09, down 2.48% today but showing strong technical momentum with bullish moving averages and recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations by 53%, and raised full-year guidance. Despite negative net margins and elevated P/E ratio of 87.85, improving operational performance and positive cash flow projections for 2026 suggest potential turnaround.
The stock presents a mixed outlook with strong technical momentum and recent operational improvements offset by valuation concerns and profitability challenges. Key opportunities include continued execution on raised guidance and debt reduction efforts, while risks center on margin pressure and high debt levels. Analyst consensus leans neutral with 55.55% hold ratings and $25.43 price target below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
